3Kim MK,Suk JH,Kwon MJ,et al.Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes[J].Diabetes Res Clin Pract,2011,92(3):322-328.
7Hammer H,Klinge A.Patients with type 2 diatetes inadequately controlled on premixed insulin:effect of initiating insulin qlargine plus oral antidiabetic agents on glycaemic control in daily practice[J].Int J Clin Pract,2007,61(12):2009-2018.
二级参考文献35
1Rizvi AA. The use of premixed insulin analogues in the treatment of patients with type 2 diabetes mellitus: advantages and limitations. Insulin, 2007,2 : 68 -79.
2Hammer H, Klinge A. Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral antidiabetic agents on glycaemie control in daily practice. Int J Clin Praet,2007,61 : 18.
4Global Guideline for Type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Meal, 2006, 23:579-593.
5Shank ML, Del Prato S, DeFronzo RA. Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM. Diabetes, 1995,44 : 165-172.
6Riddle MC. Evening insulin strategy. Diabetes Care, 1990, 13: 676-686.
7Taskinen MR, Sane T, Helve E, et aL Bedtime insulin for suppression of overnight free-fatty acid, blood glucose, and glucose production in NIDDM. Diabetes, 1989,38:580-588.
8Heinemann L, Linkeschova R, Rave K, et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care, 2000,23:644-649.
9Riddle MC, Rosenstock J, Gefich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care, 2003,26: 3080-3086.
10Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care, 2005,28:260-265.
